Meeting
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
Authors
Mark R. Middleton
Churchill Hospital, Oxford, United Kingdom
Mark R. Middleton , Philippa Corrie , Stéphane Dalle , Michal Lotem , Ruth Board , Ana Maria Arance Fernández , Frank Meiss , Patrick Terheyden , Ralf Gutzmer , Carmen Loquai , Toby Talbot , Rudolf Herbst , Katharina C. Kaehler , SRIVIDYA KOTAPATI , Trong Kim Le , Jane Brokaw , Amy Pickar Abernethy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01511913
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9531)
DOI
10.1200/JCO.2016.34.15_suppl.9531
Abstract #
9531
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert
Poster
2013 ASCO Annual Meeting
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
First Author: Paolo Antonio Ascierto
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma